Afya Shares Rise After JPMorgan Upgrade

Afya (NASDAQ:AFYA) announced a merger with Yduqs, expecting BRL 2.2B in synergies. The companies will operate independently until integration. Afya reported 21% revenue and 22% EBITDA growth from 2021-2026, returning BRL 1.1B to shareholders. The merger could expand Afya's medical education pipeline and improve trading liquidity.

JPMorgan upgraded Afya Ltd. (AFYA) to Overweight, citing merger synergies of R$1.8 billion and a premium higher education company. The price target was lowered to $19.00 from $21.00. Afya reported Q2 2026 revenue growth of 6% and H1 growth of 7%, with net income rising 14% in Q2 and 7% in H1. The company trades at a P/E ratio of 8 and a 23% free cash flow yield.

Afya Limited's (AFYA) controlling shareholders agreed to support its merger into YDUQS, with transfer limits and penalties, pending approvals. The deal requires investor EGMs and CADE antitrust clearance. The exchange ratio and regulatory timing will be key catalysts.

Afya Limited (AFYA) agreed to merge into YDUQS, with Afya shareholders receiving YDUQS shares at a fixed 6.408347 ratio and expected to own 69% of the combined company. The deal is subject to approvals, including CADE and EGMs.

Afya and Yduqs, Brazil's largest medical-education network and education group, confirmed early-stage merger talks on 24 August 2026. Yduqs shares rose 12.1% in São Paulo, while Afya's shares in New York increased 0.77%. The companies' second-quarter financials showed contrasting performances, with Afya in a stronger position. No binding agreements or details have been finalized, and both companies emphasized the preliminary nature of the discussions.

Afya (AFYA) reported Q2 2026 revenue of BRL 1.985 billion, up 7% YoY. Adjusted EBITDA rose 3% to BRL 918 million, while net income increased 7% to BRL 463 million. The company faces AI competition in clinical decision tools but is integrating AI into its iClinic platform. Management reaffirmed its full-year EBITDA guidance of BRL 1.7-1.8 billion.